Hi all - FYI my registration for this briefing has been confirmed, though it took a couple of days over the long weekend. For interest, here are my draft questions:
1. Has the Elanco Phase II Dog Dossier been submitted and what are the next milestones for an agreement?
2. When will the MPL Phase II Human Cancer trial design be communicated and when will it start?
3. What are the next steps for MPL SARS-CoVID trials and how well does this fit with PAA Strategy?
4. Is the Epichem customer contract pipeline growing and profitable in these challenging times?
If there are better questions that I can ask let me know.
Regards
Ann: Virtual Investor Briefing, page-29
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.005(3.13%) |
Mkt cap ! $80.22M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.5¢ | 16.5¢ | $276.1K | 1.636M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 379426 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |